BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Snyder N, Gajula L, Xiao SY, Grady J, Luxon B, Lau DT, Soloway R, Petersen J. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol. 2006;40:535-542. [PMID: 16825937 DOI: 10.1097/00004836-200607000-00013] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Conry SJ, Meng Q, Hardy G, Yonkers NL, Sugalski JM, Hirsch A, Davitkov P, Compan A, Falck-Ytter Y, Blanton RE. Genetically associated CD16(+)56(-) natural killer cell interferon (IFN)-αR expression regulates signaling and is implicated in IFN-α-induced hepatitis C virus decline. J Infect Dis. 2012;205:1131-1141. [PMID: 22351942 DOI: 10.1093/infdis/jis027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
2 Watanabe H, Kanematsu M, Kitagawa T, Suzuki Y, Kondo H, Goshima S, Kajita K, Bae KT, Hirose Y, Miotani S, Zhou X, Fujita H. MR elastography of the liver at 3 T with cine-tagging and bending energy analysis: preliminary results. Eur Radiol 2010;20:2381-9. [PMID: 20440504 DOI: 10.1007/s00330-010-1800-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
3 Jin W, Lin Z, Xin Y, Jiang X, Dong Q, Xuan S. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. BMC Gastroenterol. 2012;12:14. [PMID: 22333407 DOI: 10.1186/1471-230x-12-14] [Cited by in Crossref: 78] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
4 Chaudhry AA, Sulkowski MS, Chander G, Moore RD. Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort. HIV Med. 2009;10:133-142. [PMID: 19207596 DOI: 10.1111/j.1468-1293.2008.00662.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
5 Strickler HD, Howard AA, Peters M, Fazzari M, Yu H, Augenbraun M, French AL, Young M, Gange S, Anastos K, Kovacs A. The insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected women. AIDS 2008;22:527-31. [PMID: 18301066 DOI: 10.1097/QAD.0b013e3282f22cdf] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Snyder N, Nguyen A, Gajula L, Soloway R, Xiao SY, Lau DT, Petersen J. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clin Chim Acta. 2007;381:119-123. [PMID: 17442291 DOI: 10.1016/j.cca.2007.02.046] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
7 Yonkers NL, Sieg S, Rodriguez B, Anthony DD. Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection. J Infect Dis 2011;203:635-45. [PMID: 21220773 DOI: 10.1093/infdis/jiq101] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
8 Fragkos KC, Picasso Bouroncle MC, Kumar S, Caselton L, Menys A, Bainbridge A, Taylor SA, Torrealdea F, Kumagai T, Di Caro S, Rahman F, Macnaughtan J, Chouhan MD, Mehta S. Serum Scoring and Quantitative Magnetic Resonance Imaging in Intestinal Failure-Associated Liver Disease: A Feasibility Study. Nutrients 2020;12:E2151. [PMID: 32707726 DOI: 10.3390/nu12072151] [Reference Citation Analysis]
9 Patel K, Benhamou Y, Yoshida EM, Kaita KD, Zeuzem S, Torbenson M, Pulkstenis E, Subramanian GM, Mchutchison JG. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBRO Spect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. Journal of Viral Hepatitis 2009;16:178-86. [DOI: 10.1111/j.1365-2893.2008.01062.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
10 Kim SU, Ahn SH, Park JY, Kang W, Kim do Y, Park YN, Chon CY, Han KH. Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. J Clin Gastroenterol. 2009;43:267-271. [PMID: 18987556 DOI: 10.1097/mcg.0b013e31816f212e] [Cited by in Crossref: 51] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
11 Ben Jazia E, Kaabia N, Benabdelkader A, Khalifa M, Harrabi I, Braham A, Bahri F, Letaief A. Noninvasive Fibrosis Markers for the Prediction of Significant Fibrosis in Patients With Chronic Hepatitis C Virus Infection in Tunisia. Infectious Diseases in Clinical Practice 2009;17:385-7. [DOI: 10.1097/ipc.0b013e3181bf60d3] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
12 Jiang Y, Huang E, Mehrnia A, Kamgar M, Pham PT, Ogunorunyinka O, Brown I, Danovitch GM, Bunnapradist S. Can aminotransferase-to-platelet ratio index and other non-invasive markers effectively reduce liver biopsies for renal transplant evaluation of hepatitis C virus-positive patients? Nephrol Dial Transplant. 2014;29:1247-1252. [PMID: 24353319 DOI: 10.1093/ndt/gft485] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
13 Swann SA, Kaida A, Nicholson V, Brophy J, Campbell AR, Carter A, Elwood C, Gebremedhen T, Gormley R, King EM, Lee M, Lee V, Maan EJ, Magagula P, Nyman S, Pang D, Pick N, Povshedna T, Prior JC, Singer J, Tognazzini S, Murray MCM, Cote HCF. British Columbia CARMA-CHIWOS Collaboration (BCC3): protocol for a community-collaborative cohort study examining healthy ageing with and for women living with HIV. BMJ Open 2021;11:e046558. [PMID: 34362800 DOI: 10.1136/bmjopen-2020-046558] [Reference Citation Analysis]
14 Jiang ZG, Tsugawa Y, Tapper EB, Lai M, Afdhal N, Robson SC, Mukamal KJ. Low-fasting triglyceride levels are associated with non-invasive markers of advanced liver fibrosis among adults in the United States. Aliment Pharmacol Ther 2015;42:106-16. [DOI: 10.1111/apt.13216] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
15 Galal GM, Amin NF, Abdel Hafeez HA, El-Baz MA. Can serum fibrosis markers predict medium/large oesophageal varices in patients with liver cirrhosis? Arab J Gastroenterol 2011;12:62-7. [PMID: 21684475 DOI: 10.1016/j.ajg.2011.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
16 Kotlyar DS, Blonski W, Rustgi VK. Noninvasive monitoring of hepatitis C fibrosis progression. Clin Liver Dis 2008;12:557-71, viii. [PMID: 18625428 DOI: 10.1016/j.cld.2008.03.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
17 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
18 Sethi S, Simonetto DA, Abdelmoneim SS, Campion MB, Kaloiani I, Clayton AC, Kremers WK, Halling KC, Kamath PS, Talwalkar J, Shah VH. Comparison of circulating endothelial cell/platelet count ratio to aspartate transaminase/platelet ratio index for identifying patients with cirrhosis. J Clin Exp Hepatol 2012;2:19-26. [PMID: 25755402 DOI: 10.1016/S0973-6883(12)60078-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
19 Paradis V, Bedossa P. In the new area of noninvasive markers of hepatocellular carcinoma. J Hepatol 2007;46:9-11. [PMID: 17112623 DOI: 10.1016/j.jhep.2006.10.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
20 Wiegand J, Berg T. The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Dtsch Arztebl Int 2013;110:85-91. [PMID: 23451000 DOI: 10.3238/arztebl.2013.0085] [Cited by in Crossref: 16] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
21 Wang S, Zhang W, Zhang F, Qian Z, Wang LF, Ren LJ, Yang S. Value of FibroScan and aspartate aminotransferase-to-platelet ratio index, alone or in combination, in predicting esophagogastric variceal bleeding in patients with liver cirrhosis. Shijie Huaren Xiaohua Zazhi 2017; 25(14): 1287-1291 [DOI: 10.11569/wcjd.v25.i14.1287] [Reference Citation Analysis]
22 Petersen JR, Stevenson HL, Kasturi KS, Naniwadekar A, Parkes J, Cross R, Rosenberg WM, Xiao SY, Snyder N. Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C. J Clin Gastroenterol. 2014;48:370-376. [PMID: 24045284 DOI: 10.1097/mcg.0b013e3182a87e78] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
23 Snyder N, Martinez JG, Xiao SY. Chronic hepatitis C is a common associated with hepatic granulomas. World J Gastroenterol 2008; 14(41): 6366-6369 [PMID: 19009653 DOI: 10.3748/wjg.14.6366] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
24 Hua L, Andersen JW, Daar ES, Glesby MJ, Hollabaugh K, Tierney C. Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment. AIDS. 2013;27:2725-2734. [PMID: 23921611 DOI: 10.1097/01.aids.0000432470.46379.dd] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
25 Sherman M. Surveillance of Hepatocellular Carcinoma: We Must Do Better. The American Journal of Medicine 2008;121:89-90. [DOI: 10.1016/j.amjmed.2007.11.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
26 Seaman A, Ronan W, Myers L, Wheelock H, Butler M, Nelson L, E. Williams B, Zaman A. Hepatitis C Treatment Among People Who Use Drugs in an Office-Based Opioid Treatment Program Versus a Syringe Exchange Program: A Real-World Prospective Clinical Trial. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.114781] [Reference Citation Analysis]
27 Zhou Y, Sun L, Wang X, Zhou L, Li J, Liu M, Wang F, Peng J, Gui X, Zhao H, Reichenbach N, Zhou D, Ho WZ. Heroin use promotes HCV infection and dysregulates HCV-related circulating microRNAs. J Neuroimmune Pharmacol 2015;10:102-10. [PMID: 25572448 DOI: 10.1007/s11481-014-9577-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
28 So-Armah KA, Chang J, Alcorn C, Lo Re V, Baker JV, Tracy R, Butt AA, Agan BK, Rimland D, Gibert CL, Goetz MB, Oursler KK, Rodriguez-Barradas MC, Kuller LH, Brown ST, Stein JH, Skanderson M, Justice AC, Freiberg MS. HIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function. Curr HIV Res 2014;12:50-9. [PMID: 25034208 DOI: 10.2174/1570162x1201140716101512] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
29 Abd El Rihim AY, Omar RF, Fathalah W, El Attar I, Hafez HA, Ibrahim W. Role of fibroscan and APRI in detection of liver fibrosis: a systematic review and meta-analysis. Arab J Gastroenterol. 2013;14:44-50. [PMID: 23820499 DOI: 10.1016/j.ajg.2013.05.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
30 Keimburg SA, Theysohn J, Buechter M, Rashidi-alavijeh J, Willuweit K, Schneider H, Wetter A, Maasoumy B, Lange C, Wedemeyer H, Markova AA. FIB-4 and APRI as Predictive Factors for Short- and Long-Term Survival in Patients with Transjugular Intrahepatic Portosystemic Stent Shunts. Biomedicines 2022;10:1018. [DOI: 10.3390/biomedicines10051018] [Reference Citation Analysis]
31 Freshwater DA, O’Donnell K, Mutimer DJ. Inferior response of Asian vs non-Asian hepatitis C genotype 3 infection to combination antiviral therapy. J Viral Hepat. 2008;15:115-119. [PMID: 18184194 DOI: 10.1111/j.1365-2893.2007.00899.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
32 Rumbo C, Martinez MI, Cabanne A, Trentadue J, Fernández A, Gondolesi G. Utility of Aminotransferase/Platelet Ratio Index to Predict Liver Fibrosis in Intestinal Failure–Associated Liver Disease in Pediatric Patients. JPEN J Parenter Enteral Nutr 2017;41:884-9. [DOI: 10.1177/0148607115625779] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
33 Gorin JB, Malone DFG, Strunz B, Carlsson T, Aleman S, Björkström NK, Falconer K, Sandberg JK. Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection. Sci Rep 2020;10:2081. [PMID: 32034167 DOI: 10.1038/s41598-020-58768-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
34 Tanwar S, Trembling PM, Hogan BJ, Srivastava A, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM. Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy. European Journal of Gastroenterology & Hepatology 2017;29:289-96. [DOI: 10.1097/meg.0000000000000789] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
35 Gardenier D, Kwong J, Olson MC, Epstein R. Epidemiology, Screening, and Pretreatment Evaluation of the Patient With Chronic Hepatitis C Infection. The Journal for Nurse Practitioners 2015;11:109-15. [DOI: 10.1016/j.nurpra.2014.10.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Trang T, Petersen JR, Snyder N. Non-invasive markers of hepatic fibrosis in patients co-infected with HCV and HIV: comparison of the APRI and FIB-4 index. Clin Chim Acta. 2008;397:51-54. [PMID: 18692034 DOI: 10.1016/j.cca.2008.07.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
37 Trovato FM, Catalano D, Musumeci G, Trovato GM. 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics. EPMA J. 2014;5:21. [PMID: 25937854 DOI: 10.1186/1878-5085-5-21] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
38 Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Alimentary Pharmacology & Therapeutics 2009;30:557-76. [DOI: 10.1111/j.1365-2036.2009.04062.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 6.6] [Reference Citation Analysis]
39 Li J, Gordon SC, Rupp LB, Zhang T, Boscarino JA, Vijayadeva V, Schmidt MA, Lu M. The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepat. 2014;21:930-937. [PMID: 24472062 DOI: 10.1111/jvh.12224] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 8.6] [Reference Citation Analysis]
40 Mata-Marín JA, Fuentes-Allen JL, Gaytán-Martínez J, Manjarrez-Téllez B, Chaparro-Sánchez A, Arroyo-Anduiza CI. APRI as a predictor of early viral response in chronic hepatitis C patients. World J Gastroenterol 2009; 15(39): 4923-4927 [PMID: 19842223 DOI: 10.3748/wjg.15.4923] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
41 Tanwar S, Trembling PM, Hogan BJ, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM. Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid. J Clin Gastroenterol 2017;51:268-77. [PMID: 27380461 DOI: 10.1097/MCG.0000000000000581] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
42 Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, Xuan SY. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726-736. [PMID: 21319189 DOI: 10.1002/hep.24105] [Cited by in Crossref: 538] [Cited by in F6Publishing: 499] [Article Influence: 48.9] [Reference Citation Analysis]
43 Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. 2007;46:912-921. [PMID: 17705266 DOI: 10.1002/hep.21835] [Cited by in Crossref: 251] [Cited by in F6Publishing: 239] [Article Influence: 16.7] [Reference Citation Analysis]
44 Dinesen L, Caspary WF, Chapman RW, Dietrich CF, Sarrazin C, Braden B. 13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C. Dig Liver Dis. 2008;40:743-748. [PMID: 18339592 DOI: 10.1016/j.dld.2008.01.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
45 Cheung RC, Currie S, Shen H, Bini EJ, Ho SB, Anand BS, Hu KQ, Wright TL, Morgan TR;  VA HCV-001 Study Group. Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice? J Clin Gastroenterol. 2008;42:827-834. [PMID: 18285716 DOI: 10.1097/mcg.0b013e318046ea9a] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
46 Fallatah HI. Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology 2014;2014:1-15. [DOI: 10.1155/2014/357287] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
47 Bonekamp D, Bonekamp S, Geiger B, Kamel IR. An Elevated Arterial Enhancement Fraction Is Associated With Clinical and Imaging Indices of Liver Fibrosis and Cirrhosis: . Journal of Computer Assisted Tomography 2012;36:681-9. [DOI: 10.1097/rct.0b013e3182702ee3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
48 Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, Mantzoukis K, O’Brien J, Thalassinos E, Papastergiou V. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess. 2015;19:1-409, v-vi. [PMID: 25633908 DOI: 10.3310/hta19090] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 12.0] [Reference Citation Analysis]
49 Pereira AA, Jacobson IM. Modern diagnosis of HBV infection. Curr hepatitis rep 2009;8:18-25. [DOI: 10.1007/s11901-009-0003-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Siddiqui FA, Ehrinpreis MN, Janisse J, Dhar R, May E, Mutchnick MG. Demographics of a large cohort of urban chronic hepatitis C patients. Hepatol Int 2008;2:376-81. [PMID: 19669268 DOI: 10.1007/s12072-008-9086-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
51 Pockros PJ. Noninvasive Markers of Fibrosis in Chronic Hepatitis Patients: . Journal of Clinical Gastroenterology 2006;40:461-3. [DOI: 10.1097/00004836-200607000-00001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
52 Fayed HM, Mahmoud HS, Elaiw Mohamed Ali A. The Utility of Retinol-Binding Protein 4 in Predicting Liver Fibrosis in Chronic Hepatitis C Patients in Response to Direct-Acting Antivirals. Clin Exp Gastroenterol 2020;13:53-63. [PMID: 32110084 DOI: 10.2147/CEG.S229689] [Reference Citation Analysis]
53 Ayoub F, Trillo-Alvarez C, Morelli G, Lascano J. Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease. World J Hepatol 2018; 10(1): 34-40 [PMID: 29399276 DOI: 10.4254/wjh.v10.i1.34] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
54 Izumi G, Takeda A, Yamazawa H, Sasaki O, Kato N, Asai H, Tachibana T, Matsui Y. Forns Index is a predictor of cardiopulmonary bypass time and outcomes in Fontan conversion. Heart Vessels 2020;35:586-92. [PMID: 31562553 DOI: 10.1007/s00380-019-01515-w] [Reference Citation Analysis]
55 Bichoupan K, Tandon N, Martel-Laferriere V, Patel NM, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D, Linderman M, Olson W, Perumalswami PV, Schiano TD, Odin JA, Liu LU, Dieterich DT, Branch AD. Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. World J Hepatol 2017; 9(11): 551-561 [PMID: 28469811 DOI: 10.4254/wjh.v9.i11.551] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
56 Mummadi RR, Petersen JR, Xiao SY, Snyder N. Role of simple biomarkers in predicting fibrosis progression in HCV infection. World J Gastroenterol 2010; 16(45): 5710-5715 [PMID: 21128320 DOI: 10.3748/wjg.v16.i45.5710] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
57 Yu C, Gifford AL, Christiansen CL, Drainoni ML. Hepatitis C Is Poorly Associated With Drug Use in Cambodian Americans in Lowell, Massachusetts. Open Forum Infect Dis 2016;3:ofw099. [PMID: 27419171 DOI: 10.1093/ofid/ofw099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
58 Wang T, Shao C, Zhang G, Xu Y. Real-time elastography (RTE): a valuable sonography-based non-invasive method for the assessment of liver fibrosis in chronic hepatitis B. Abdom Radiol (NY) 2017;42:2632-8. [PMID: 28527146 DOI: 10.1007/s00261-017-1186-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
59 Poynard T, Bruix J, Schiff ER, Diago M, Berg T, Moreno-Otero R, Lyra AC, Carrilho F, Griffel LH, Boparai N, Jiang R, Burroughs M, Brass CA, Albrecht JK. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study. J Hepatol 2013;58:452-9. [PMID: 23159770 DOI: 10.1016/j.jhep.2012.11.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
60 Kim KE, Park MS, Chung S, An C, Axel L, Ergashovna RG. Magnetization-tagged MRI is a simple method for predicting liver fibrosis. Clin Mol Hepatol 2016;22:140-5. [PMID: 27044764 DOI: 10.3350/cmh.2016.22.1.140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
61 Jiang ZG, Feldbrügge L, Tapper EB, Popov Y, Ghaziani T, Afdhal N, Robson SC, Mukamal KJ. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. Aliment Pharmacol Ther 2016;43:734-43. [DOI: 10.1111/apt.13515] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
62 Potts J, Maybury C, Salam A, Barker J, Agarwal K, Smith C. Diagnosing liver fibrosis: a narrative review of current literature for dermatologists. Br J Dermatol 2017;177:637-44. [DOI: 10.1111/bjd.15246] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
63 Bhogal H, Sterling RK. Staging of liver disease: which option is right for my patient? Infect Dis Clin North Am. 2012;26:849-861. [PMID: 23083819 DOI: 10.1016/j.idc.2012.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
64 Chakrabarty G, Bruce M, Horner M, Wang B, Agarwal K, Carey I. Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients? J Viral Hepat 2018;25:80-7. [PMID: 28710798 DOI: 10.1111/jvh.12756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Colletta C, Smirne C, Marini C, Pirisi M. Liver Biopsy and Noninvasive Alternatives in Relationship to the Duration of Antiviral Treatment for Hepatitis C. Journal of Clinical Gastroenterology 2008;42:219-20. [DOI: 10.1097/01.mcg.0000225661.23179.6d] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
66 Li SM, Li GX, Fu DM, Wang Y, Dang LQ. Liver fibrosis evaluation by ARFI and APRI in chronic hepatitis C. World J Gastroenterol 2014; 20(28): 9528-9533 [PMID: 25071348 DOI: 10.3748/wjg.v20.i28.9528] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
67 Burrage L, Zimmerman H, Higgins S, Param K, Orme C, Mitchell J, O'Beirne J. Performance of simple serum-based tests to exclude cirrhosis prior to hepatitis C treatment in non-hospital settings in Australia. Intern Med J 2021;51:533-9. [PMID: 31994285 DOI: 10.1111/imj.14767] [Reference Citation Analysis]
68 Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, Karpov I, Galli M, Domingo P, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. AIDS 2015;29:1205-15. [PMID: 25870984 DOI: 10.1097/QAD.0000000000000674] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
69 Zeng DW, Liu YR, Zhang JM, Zhu YY, Lin S, You J, Li YB, Chen J, Zheng Q, Jiang JJ, Dong J. Serum ceruloplasmin levels correlate negatively with liver fibrosis in males with chronic hepatitis B: a new noninvasive model for predicting liver fibrosis in HBV-related liver disease. PLoS One. 2013;8:e77942. [PMID: 24282481 DOI: 10.1371/journal.pone.0077942] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
70 Woolfson JP, Schreiber RA, Raveendran S, Chilvers M, Barker C, Guttman OR. Role of transient elastography and APRI in the assessment of pediatric cystic fibrosis liver disease. CanLivJ 2021;4:23-32. [DOI: 10.3138/canlivj-2020-0008] [Reference Citation Analysis]
71 Reyes-Avilés E, Kostadinova L, Rusterholtz A, Cruz-Lebrón A, Falck-Ytter Y, Anthony DD. Presence of Rheumatoid Factor during Chronic HCV Infection Is Associated with Expansion of Mature Activated Memory B-Cells that Are Hypo-Responsive to B-Cell Receptor Stimulation and Persist during the Early Stage of IFN Free Therapy. PLoS One 2015;10:e0144629. [PMID: 26649443 DOI: 10.1371/journal.pone.0144629] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
72 Tseng PL, Wang JH, Hung CH, Tung HD, Chen TM, Huang WS, Liu SL, Hu TH, Lee CM, Lu SN. Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations. Kaohsiung J Med Sci. 2013;29:385-395. [PMID: 23768703 DOI: 10.1016/j.kjms.2012.11.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
73 Patton HM, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D, Molleston J; Nonalcoholic Steatohepatitis Clinical Research Network. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 2008;135:1961-1971.e2. [PMID: 19013463 DOI: 10.1053/j.gastro.2008.08.050] [Cited by in Crossref: 165] [Cited by in F6Publishing: 160] [Article Influence: 11.8] [Reference Citation Analysis]
74 Selph SS, Ginsburg AD, Chou R. Impact of contacting study authors to obtain additional data for systematic reviews: diagnostic accuracy studies for hepatic fibrosis. Syst Rev 2014;3:107. [PMID: 25239493 DOI: 10.1186/2046-4053-3-107] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
75 El-attar MM, Rashed HG, Sewify EM, Hassan HE. A suggested algorithm for using serum biomarkers for the diagnosis of liver fibrosis in chronic hepatitis C infection. Arab Journal of Gastroenterology 2010;11:206-11. [DOI: 10.1016/j.ajg.2010.09.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
76 Snyder N, Petersen JR. The APRI and the RVR. J Clin Gastroenterol 2009;43:500-1. [PMID: 19098684 DOI: 10.1097/MCG.0b013e318178e57a] [Reference Citation Analysis]
77 Ahmad W, Ijaz B, Javed FT, Gull S, Kausar H, Sarwar MT, Asad S, Shahid I, Sumrin A, Khaliq S, Jahan S, Pervaiz A, Hassan S. A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol 2011;11:44. [PMID: 21507271 DOI: 10.1186/1471-230X-11-44] [Cited by in Crossref: 52] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]